Abstract

Disseminated intravascular coagulation (DIC) can be correctly redefined as disseminated intravascular microthrombosis based on “two-path unifying theory” of in vivo hemostasis. “DIC” is a form of vascular microthrombotic disease characterized by “microthrombi” composed of platelets and unusually large von Willebrand factor multimers (ULVWF). Microthrombotic disease includes not only “DIC”, but also microthrombosis occurring in thrombotic thrombocytopenic purpura (TTP), TTP-like syndrome, and focal, multifocal and localized microthrombosis. Being a hemostatic disease, microthrombotic disease occurs as a result of lone activation of ULVWF path via partial in vivo hemostasis. In endothelial injury associated with critical illnesses such as sepsis, the vascular damage is limited to the endothelial cell and activates ULVWF path. In contrast, in intravascular traumatic injury, the local damage may extend from the endothelial cell to subendothelial tissue and sometimes beyond, and activates both ULVWF and tissue factor (TF) paths. When endotheliopathy triggers exocytosis of ULVWF and recruits platelets, ULVWF path is activated and promotes microthrombogenesis to produce microthrombi composed of microthrombi strings, but when localized vascular damage causes endothelial and subendothelial tissue damage, both ULVWF and TF paths are activated and promote macrothrombogenesis to produce macrothrombus made of complete “blood clots”. Currently, “DIC” concept is ascribed to activated TF path leading to fibrin clots. Instead, it should be correctly redefined as microthrombosis caused by activation of ULVWF path, leading to endotheliopathy-associated microthrombosis. The correct term for acute “DIC” is disseminated microthrombosis-associated hepatic coagulopathy, and that for chronic “DIC” is disseminated microthrombosis without hepatic coagulopathy. TTP-like syndrome is hematologic phenotype of endotheliopathy-associated microthrombosis. This correct concept of “DIC” is identified from novel theory of “in vivo hemostasis”, which now can solve every mystery associated with “DIC” and other associated thrombotic disorders. Thus, sepsis-associated coagulopathy is not “DIC”, but is endotheliopathy-associated vascular microthrombotic disease.

Highlights

  • Since the introduction of term disseminated intravascular coagulation (DIC) by Donald McKay [1] early 1950s for a mysterious thrombo-hemorrhagic syndrome, many blood coagulation scientists, pathologists and clinicians have ardently searched for the genuine nature of this most feared and deadly disease more than 60 years

  • This author has proposed two novel theories based on vascular wall physiology and hemostasis in vascular injury; one is the molecular pathogenesis of endotheliopathy [2] illustrated in Fig. 1 to explore the mechanism of inflammation and coagulation, and the other is a in vivo hemostatic theory [3] presented in Fig. 2a, which is modeled on physiologic changes from the damage of the blood vessel wall, activating unusually large von Willebrand factor (ULVWF) path and tissue factor (TF) path in hemostasis [3, 4]

  • Unsettled theories for the pathogenesis of “disseminated intravascular coagulation” When we look back the medical history since its initial description of “DIC” based on ill-founded concept, the medical literature is replete with published articles on the enigmatic nature of the pathophysiological mechanism of “DIC” from many bright minds of coagulation science and clinical medicine [25,26,27,28,29,30,31,32,33,34,35,36,37,38,39]

Read more

Summary

Background

Since the introduction of term disseminated intravascular coagulation (DIC) by Donald McKay [1] early 1950s for a mysterious thrombo-hemorrhagic syndrome, many blood coagulation scientists, pathologists and clinicians have ardently searched for the genuine nature of this most feared and deadly disease more than 60 years. Please consider that contemporary in vitro hemostatic theory (i.e., extrinsic cascade) has been borne out from clotting studies in laboratory “test tubes”, in which the glass wall does not release ULVWF and TF, nor recruit the platelets from circulation Armed with this fundamental derived from vascular wall physiology, the concept of in vivo hemostasis is reconstructed to explicate how hemostasis is initiated and leads to blood coagulation to make bleeding stop in external bodily injury, and the mechanism of thrombogenesis is proposed to explain how three different paths of blood clot formation take place in intravascular injury through one hemostatic system. The term “coagulation” in vivo and in vitro, “thrombosis” (microthrombosis and macrothrombosis) in vivo, “fibrin clot” in vivo and in vitro, and “blood clots” in vivo and in vitro which have been

Participants
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call